Dimensional Fund Advisors LP lifted its holdings in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 28.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 924,078 shares of the company's stock after acquiring an additional 205,398 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.57% of Annexon worth $5,115,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of ANNX. CIBC Bancorp USA Inc. bought a new position in Annexon in the 3rd quarter valued at $31,000. Engineers Gate Manager LP acquired a new stake in shares of Annexon in the second quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company's stock valued at $35,000 after buying an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in Annexon during the 4th quarter worth about $50,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Annexon during the 4th quarter worth about $52,000.
Analysts Set New Price Targets
ANNX has been the subject of several research reports. Cantor Fitzgerald restated an "overweight" rating on shares of Annexon in a research report on Monday, July 13th. Wall Street Zen lowered shares of Annexon from a "hold" rating to a "sell" rating in a research report on Sunday, July 12th. Needham & Company LLC increased their price target on shares of Annexon from $11.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. HC Wainwright reissued a "buy" rating and issued a $14.00 price target on shares of Annexon in a report on Monday, July 20th. Finally, The Goldman Sachs Group started coverage on Annexon in a report on Tuesday, May 12th. They set a "neutral" rating and a $7.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Annexon currently has an average rating of "Hold" and an average price target of $15.33.
Get Our Latest Analysis on Annexon
Annexon Trading Down 0.9%
Annexon stock opened at $5.34 on Wednesday. Annexon, Inc. has a 1 year low of $2.03 and a 1 year high of $7.18. The company has a market cap of $874.91 million, a PE ratio of -4.38 and a beta of 1.18. The company's 50-day moving average is $5.35 and its two-hundred day moving average is $5.54.
Insider Activity at Annexon
In other Annexon news, Director Muneer A. Satter purchased 613,497 shares of the company's stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average cost of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the purchase, the director directly owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This represents a 6.31% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.31% of the stock is currently owned by corporate insiders.
Annexon Company Profile
(
Free Report)
Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.
Featured Articles
Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
